Dr Dale Shepard of Cleveland Clinic discusses the PYNNACLE trial results for rezatapopt, the first successful small-molecule reactivation of mutant p53.
Dale Shepard, MD, PhD
Dale Shepard, MD, PhD, is a hematologist/oncologist at the Cleveland Clinic.
Articles by Dale Shepard, MD, PhD
Dale Shepard, MD, PhD, discusses the key themes emerging from the 2025 ASCO Annual Meeting, highlighting a prevailing sense of optimism driven by ongoing research.
